bioAffinity Technologies Closes $1.5M Private Placement
Ticker: BIAFW · Form: 8-K · Filed: Mar 7, 2025 · CIK: 1712762
Sentiment: neutral
Topics: private-placement, funding, biotechnology
Related Tickers: BIAF
TL;DR
BIAF closed a $1.5M private placement, selling stock & warrants. Funds for growth.
AI Summary
On March 6, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing several events. The company announced the closing of a private placement offering, raising approximately $1.5 million in gross proceeds before deducting offering expenses. This offering involved the sale of 1,500,000 shares of its common stock and warrants to purchase an equal number of shares at an exercise price of $1.00 per share. The filing also included financial statements and exhibits related to these transactions.
Why It Matters
This capital raise provides bioAffinity Technologies with crucial funding, potentially enabling further research and development or operational expansion, which could impact its future growth trajectory.
Risk Assessment
Risk Level: medium — The company's reliance on private placements for funding and the nature of its research and development activities in the biotechnology sector present inherent risks.
Key Numbers
- $1.5M — Gross Proceeds (Raised from private placement offering)
- 1,500,000 — Shares Sold (Common stock shares in the private placement)
- $1.00 — Warrant Exercise Price (Price to purchase common stock via warrants)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- March 6, 2025 (date) — Date of earliest event reported
- $1.5 million (dollar_amount) — Gross proceeds from private placement
- 1,500,000 shares (dollar_amount) — Number of common stock shares sold
- $1.00 (dollar_amount) — Exercise price of warrants
FAQ
What was the total amount of gross proceeds raised in the private placement?
The company raised approximately $1.5 million in gross proceeds before deducting offering expenses.
What securities were sold in the private placement?
The private placement involved the sale of 1,500,000 shares of common stock and warrants to purchase an equal number of shares.
What is the exercise price for the warrants issued?
The warrants have an exercise price of $1.00 per share.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 6, 2025.
What is the principal business address of bioAffinity Technologies, Inc.?
The principal executive address is 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 7, 2025 regarding bioAffinity Technologies, Inc. (BIAFW).